Adamis Pharmaceuticals (ADMP) Revenue & Revenue Breakdown
Adamis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$4.76M
Latest Revenue (Q)
$9.06M
Main Segment (Y)
Compounded Pharmaceuticals
Main Geography (Y)
Compounded Pharmaceuticals
Adamis Pharmaceuticals Revenue by Period
Adamis Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2022-12-31 | $4.76M | 115.34% |
| 2021-12-31 | $2.21M | -86.64% |
| 2020-12-31 | $16.53M | -25.26% |
| 2019-12-31 | $22.11M | 46.58% |
| 2018-12-31 | $15.09M | 15.40% |
| 2017-12-31 | $13.07M | 101.94% |
| 2016-12-31 | $6.47M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-03-31 | - | -100.00% |
| 2010-03-31 | $290.29K | -56.02% |
| 2009-03-31 | $660.00K | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | -100.00% |
| 2006-12-31 | $2.66M | -79.27% |
| 2005-12-31 | $12.84M | 394.34% |
| 2004-12-31 | $2.60M | 60.27% |
| 2003-12-31 | $1.62M | 15.58% |
| 2003-01-13 | $1.40M | 59.73% |
| 2001-12-31 | $877.49K | -44.66% |
| 2000-12-31 | $1.59M | 58.56% |
| 1999-12-31 | $1.00M | 25.00% |
| 1998-12-31 | $800.00K | - |
| 1997-12-31 | $800.00K | 33.33% |
| 1996-12-31 | $600.00K | -40.00% |
| 1995-12-31 | $1.00M | 100.00% |
| 1994-12-31 | - | -100.00% |
| 1993-12-31 | $90.00K | - |
Adamis Pharmaceuticals generated $4.76M in revenue during NA 2022, up 115.34% compared to the previous quarter, and up 36.38% compared to the same period a year ago.
Adamis Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $9.06M | 130382.36% |
| 2023-06-30 | $6.95K | -99.52% |
| 2023-03-31 | $1.45M | -32.44% |
| 2022-12-31 | $2.15M | 42.84% |
| 2022-09-30 | $1.51M | 3678.66% |
| 2022-06-30 | $39.85K | -96.55% |
| 2022-03-31 | $1.15M | -199.58% |
| 2021-12-31 | $-1.16M | -252.56% |
| 2021-09-30 | $759.96K | -81.05% |
| 2021-06-30 | $4.01M | -2.37% |
| 2021-03-31 | $4.11M | 12.95% |
| 2020-12-31 | $3.64M | -15.42% |
| 2020-09-30 | $4.30M | 9.53% |
| 2020-06-30 | $3.93M | -15.80% |
| 2020-03-31 | $4.66M | -15.83% |
| 2019-12-31 | $5.54M | -6.15% |
| 2019-09-30 | $5.90M | 2.40% |
| 2019-06-30 | $5.76M | 17.51% |
| 2019-03-31 | $4.91M | 18.10% |
| 2018-12-31 | $4.15M | 8.37% |
| 2018-09-30 | $3.83M | -2.24% |
| 2018-06-30 | $3.92M | 23.32% |
| 2018-03-31 | $3.18M | 11.87% |
| 2017-12-31 | $2.84M | -16.13% |
| 2017-09-30 | $3.39M | -10.96% |
| 2017-06-30 | $3.81M | 25.26% |
| 2017-03-31 | $3.04M | 22.99% |
| 2016-12-31 | $2.47M | 18.98% |
| 2016-09-30 | $2.08M | 7.67% |
| 2016-06-30 | $1.93M | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | -100.00% |
| 2010-03-31 | $-60.80K | -151.20% |
| 2009-12-31 | $118.75K | -5.66% |
| 2009-09-30 | $125.87K | 18.22% |
| 2009-06-30 | $106.47K | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2007-09-30 | - | - |
Adamis Pharmaceuticals generated $9.06M in revenue during Q3 2023, up 130382.36% compared to the previous quarter, and up 22741.99% compared to the same period a year ago.
Adamis Pharmaceuticals Revenue Breakdown
Adamis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Compounded Pharmaceuticals | $13.75M | - | - |
| Sterile Product | $9.16M | - | - |
| Manufactured Product, Other | $2.78M | - | - |
| Non-Sterile Product | $4.59M | - | - |
| Outsourced Manufacturing | - | $3.76M | - |
| Non-Sterile | - | $4.86M | $5.97M |
| Sterile | - | $13.50M | $9.12M |
Adamis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Compounded Pharmaceuticals (45.41%), Sterile Product (30.27%), Non-Sterile Product (15.15%), and Manufactured Product, Other (9.17%).
Quarterly Revenue by Product
| Product/Service | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sterile Product | $1.65M | $1.63M | $1.92M | $2.24M | $1.98M | - | - | - | - | - | - | - | - |
| Manufactured Product, Other | $1.28M | $1.33M | $679.79K | $868.08K | $721.43K | - | - | - | - | - | - | - | - |
| Compounded Pharmaceuticals | $2.74M | $2.78M | $2.96M | $3.43M | $3.20M | - | - | - | - | - | - | - | - |
| Non-Sterile Product | $1.08M | $1.15M | $1.04M | $1.19M | $1.22M | - | - | - | - | - | - | - | - |
| Outsourced Manufacturing | - | - | - | - | - | $507.28K | $831.24K | $1.35M | $1.12M | $464.99K | - | - | - |
| Non-Sterile | - | - | - | - | - | $1.10M | $1.08M | $1.19M | $1.32M | $1.27M | $1.54M | $1.81M | $1.41M |
| Sterile | - | - | - | - | - | $3.05M | $3.63M | $3.37M | $3.32M | $3.17M | $2.30M | $2.11M | $1.77M |
Adamis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Compounded Pharmaceuticals (40.55%), Sterile Product (24.52%), Manufactured Product, Other (18.90%), and Non-Sterile Product (16.02%).
Adamis Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Compounded Pharmaceuticals | $13.75M | - | - |
| Sterile Product | $9.16M | - | - |
| Non-Sterile Product | $4.59M | - | - |
| Manufactured Product, Other | $2.78M | - | - |
| Sterile | - | $13.50M | $9.12M |
| Outsourced Manufacturing | - | $3.76M | - |
| Non-Sterile | - | $4.86M | $5.97M |
Adamis Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: Compounded Pharmaceuticals (45.41%), Sterile Product (30.27%), Non-Sterile Product (15.15%), and Manufactured Product, Other (9.17%).
Quarterly Revenue by Country
| Country | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufactured Product, Other | $1.28M | $1.33M | $679.79K | $868.08K | $721.43K | - | - | - | - | - | - | - | - |
| Compounded Pharmaceuticals | $2.74M | $2.78M | $2.96M | $3.43M | $3.20M | - | - | - | - | - | - | - | - |
| Sterile Product | $1.65M | $1.63M | $1.92M | $2.24M | $1.98M | - | - | - | - | - | - | - | - |
| Non-Sterile Product | $1.08M | $1.15M | $1.04M | $1.19M | $1.22M | - | - | - | - | - | - | - | - |
| Sterile | - | - | - | - | - | $3.05M | $3.63M | $3.37M | $3.32M | $3.17M | $2.30M | $2.11M | $1.77M |
| Outsourced Manufacturing | - | - | - | - | - | $507.28K | $831.24K | $1.35M | $1.12M | $464.99K | - | - | - |
| Non-Sterile | - | - | - | - | - | $1.10M | $1.08M | $1.19M | $1.32M | $1.27M | $1.54M | $1.81M | $1.41M |
Adamis Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 21: Compounded Pharmaceuticals (40.55%), Sterile Product (24.52%), Manufactured Product, Other (18.90%), and Non-Sterile Product (16.02%).
Adamis Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTLT | Catalent | $4.28B | $1.07B |
| TLRY | Tilray Brands | $788.94M | $188.34M |
| ORGO | Organogenesis | $433.14M | $130.23M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| ACRX | Talphera | $651.00K | $117.00K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
ADMP Revenue FAQ
What is Adamis Pharmaceuticals’s yearly revenue?
Adamis Pharmaceuticals's yearly revenue for 2022 was $4.76M, representing an increase of 115.34% compared to 2021. The company's yearly revenue for 2021 was $2.21M, representing a decrease of -86.64% compared to 2020. ADMP's yearly revenue for 2020 was $16.53M, representing a decrease of -25.26% compared to 2019.
What is Adamis Pharmaceuticals’s quarterly revenue?
Adamis Pharmaceuticals's quarterly revenue for Q3 2023 was $9.06M, a 130382.36% increase from the previous quarter (Q2 2023), and a 501.85% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $6.94K, a -99.52% decrease from the previous quarter (Q1 2023), and a -82.57% decrease year-over-year (Q2 2022). ADMP's quarterly revenue for Q1 2023 was $1.45M, a -32.44% decrease from the previous quarter (Q4 2022), and a 25.85% increase year-over-year (Q1 2022).
What is Adamis Pharmaceuticals’s revenue growth rate?
Adamis Pharmaceuticals's revenue growth rate for the last 3 years (2020-2022) was -71.22%, and for the last 5 years (2018-2022) was -68.47%.
What are Adamis Pharmaceuticals’s revenue streams?
Adamis Pharmaceuticals's revenue streams in c 20 are Compounded Pharmaceuticals, Sterile Product, Manufactured Product, Other, and Non-Sterile Product. Compounded Pharmaceuticals generated $13.75M in revenue, accounting 45.41% of the company's total revenue Sterile Product generated $9.16M in revenue, accounting 30.27% of the company's total revenue Manufactured Product, Other generated $2.78M in revenue, accounting 9.17% of the company's total revenue Non-Sterile Product generated $4.59M in revenue, accounting 15.15% of the company's total revenue
What is Adamis Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Adamis Pharmaceuticals was Compounded Pharmaceuticals. This segment made a revenue of $13.75M, representing 45.41% of the company's total revenue.